Copyright © Inderes 2011 - present. All rights reserved.

Biohit

1,925EUR
4.490 investorer følger denne virksomhed

Biohit is a medical technology company. The company develops and manufactures laboratory equipment, supplies, and diagnostic analysis systems adapted for research, care, and industrial laboratories. In addition to the main activities, technical support, maintenance, and training services are offered within the mentioned work area. The largest presence is in the Nordic market. The company is headquartered in Helsinki.

P/E (23e)
18,13
EV/EBIT (adj.) (23e)
12
P/B (23e)
3,17
Udbytteafkast, % (23e)
-
Kursmål
2.40 EUR
Anbefaling
Akkumulér
Opdateret
10.8.2023
NASDAQ Helsinki
BIOBV
Daglig lav / høj pris
-
Markedsværdi
23,37 mio. EUR
Aktieomsætning
-
Volumen
-
Risiko og anbefaling
HøjRisikoLav
SælgAnbefalingKøb

Seneste analyser

Biohit: Positive result from H1 test
10.08.2023
Biohit: Sustainability of turnaround being tested
02.07.2023

Extensive report

Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the report

Analyst

Antti Siltanen
Antti Siltanen
Analytiker

Seneste videoer

Biohit: Preconditions for a turnaround
03.07.2023

Major Owners
Source: Millistream Market Data AB

OwnerCapitalVotes
Biohit Healthcare (Hefei) Co., Ltd.32,7 %29,4 %
Suovaniemi Osmo Antero13,4 %56,3 %
Premium
Not activated

This content is for our Premium customers only.

Sign inLearn more

Insider Transactions

InsiderDateTotal value
Panu Hendolin24.08.20236.390EUR
Panu Hendolin23.08.2023800EUR
Premium
Not activated

This content is for our Premium customers only.

Sign inLearn more

Resultatopgørelse

20192020202120222023e2024e2025e2026e
Omsætning10,057,129,3610,9512,4013,6314,7915,90
vækst-%1,22 %-29,14 %31,42 %16,99 %13,23 %9,90 %8,52 %7,52 %
EBITDA0,59-1,180,511,612,362,623,133,72
EBIT (adj.)-1,41-3,17-1,481,131,912,172,632,88
EBIT-1,41-3,17-1,481,131,912,172,632,88
Overskud før skat-1,23-3,26-1,300,872,112,172,632,88
Netto indkomst-1,42-3,31-1,500,601,611,972,102,30
EPS (adj.)-0,09-0,22-0,100,040,110,130,140,15
vækst-%165,85 %22,99 %6,42 %9,51 %
Udbytte0,000,000,000,000,000,050,060,07
Udbytte ratio38,28 %43,17 %45,99 %

Profitability and return on capital

20192020202120222023e2024e2025e2026e
EBITDA-%5,91 %-16,52 %5,43 %14,69 %18,99 %19,25 %21,17 %23,38 %
EBIT-% (adj.)-14,05 %-44,56 %-15,81 %10,30 %15,36 %15,95 %17,76 %18,09 %
EBIT-%-14,05 %-44,56 %-15,81 %10,30 %15,36 %15,95 %17,76 %18,09 %
ROE-9,23 %-28,25 %-18,55 %8,05 %19,18 %19,44 %17,78 %17,45 %
ROI-8,89 %-25,92 %-17,70 %14,27 %20,73 %19,77 %20,45 %20,17 %

Værdiansættelse

20192020202120222023e2024e2025e2026e
Share price (EUR)3,362,481,841,571,931,931,931,93
Aktier15,0515,0515,0515,0515,1115,1115,1115,11
Markedsværdi50,5537,3127,6123,6229,0929,0929,0929,09
Enterprise value41,8831,6222,2718,3422,8521,3920,5019,64
EV/S4,174,442,381,671,841,571,391,24
EV/EBITDA70,50-43,8311,409,708,156,555,28
EV/EBIT (adj.)---16,2612,009,847,816,83
EV/EBIT---16,2612,009,847,816,83
P/E (adj.)---39,3018,1314,7413,8512,65
P/E---39,3018,1314,7413,8512,65
P/B3,454,243,743,123,172,612,332,10
P/S5,035,242,952,162,352,131,971,83
Udbytteprocent2,60 %3,12 %3,64 %
Equity ratio84,41 %81,57 %76,71 %68,68 %73,36 %76,17 %77,58 %78,94 %
Gearing ratio-59,18 %-64,71 %-72,42 %-69,82 %-68,04 %-69,17 %-68,83 %-68,11 %

Kvartalsdata

Q1/22Q2/22Q3/22Q4/222022Q1/23eQ2/23Q3/23eQ4/23e
Omsætning6,10-6,1010,9510,956,505,90
EBITDA1,50-1,501,611,611,750,66
EBIT1,30-1,301,131,131,500,41
Overskud før skat1,10-1,100,870,871,500,41
Netto indkomst0,90-0,900,600,601,400,31
ViserAlle indholdstyper
Publisher
Analytikerkommentar
af Antti Siltanen

Biohit renewed its strategy and targets until 2028

Biohit

Biohit announced its renewed strategy for 2024-2028 on Wednesday. The main objective of the strategy is strong and profitable growth, which the company seeks both organically and through carefully considered acquisitions. The product portfolio remains essentially unchanged and the update did not include any surprises in this respect.

Publisher
Analytikerkommentar
af Antti Siltanen

Biohit’s Q3 has followed the stepping stones

Biohit

Biohit that reports semi-annually does not publish business reviews for Q1 and Q3 but the company reports on its progress in the CEO’s blog. The company’s message concerning business development during Q3 is positive and in line with our expectations.

Publisher
Analyse
af Antti Siltanen

Biohit: Positive result from H1 test

Biohit

Biohit's H1 report exceeded our expectations in terms of both revenue and earnings. The launch of the GastroPanel® fingertip blood test, during H1 and the partial periodization of China's revenue to H2 strengthen our growth expectations for the near future.

Publisher
Analytikerkommentar
af Antti Siltanen

Biohit H1 on Wednesday: Looking East

Biohit

Biohit will release its H1 report on Wednesday August 8 at 9:30 am EEST. We expect revenue of EUR 5.8 million and EBIT of EUR 0.8 million, driven especially by the multi-year China distribution agreement renewed last year. Interest is also directed at information on the sales of Gastropanel® products, and especially the new fingerprick test, and its outlook after last year’s supply chain challenges.